Genetic Testing Strategies for Unexplained Sudden Cardiac Death Cases

Gallagher Brito^*
*Correspondence: Gallagher Brito, Department of Medicine, University of Campania “Luigi Vanvitelli”, Luciano Armanni 5, 80138 Naples, Italy, Email:

Keywords

Unexplained sudden cardiac death • Genetic testing • Targeted sequencing • Next-generation sequencing • Whole exome sequencing • Variant interpretation • Genetic counseling

Introduction

Unexplained Sudden Cardiac Death (USCD) continues to present a daunting challenge in clinical practice, often striking individuals without prior warning or identifiable risk factors. Defined as the unexpected death due to cardiac causes within one hour of symptom onset in a previously asymptomatic individual or within 24 hours of having been observed alive and symptom-free, USCD accounts for a significant proportion of sudden cardiac deaths worldwide. While advancements in cardiovascular medicine have improved our understanding of various cardiac disorders, a subset of cases remains enigmatic, leaving families grappling with unanswered questions and healthcare providers seeking effective diagnostic strategies. Genetic testing has emerged as a promising approach in elucidating the underlying genetic factors contributing to USCD. In recent years, significant progress has been made in unraveling the genetic basis of inherited cardiac conditions, including cardiomyopathies, arrhythmias and ion channelopathies, which can predispose individuals to sudden cardiac death. Understanding the genetic underpinnings of these conditions not only aids in the identification of at-risk family members but also informs clinical management and risk stratification strategies [1].

One of the primary genetic testing strategies employed in USCD cases is targeted gene sequencing, which involves analyzing a specific set of genes known to be associated with cardiac disorders. This focused approach is particularly useful when there is clinical suspicion or a family history suggestive of a specific inherited cardiac condition. For instance, in cases where Hypertrophic Cardiomyopathy (HCM) is suspected, sequencing of genes such as MYH7, MYBPC3 and TNNT2 may be prioritized. Targeted gene sequencing offers a cost-effective and efficient means of identifying pathogenic variants within known disease-associated genes. Next-Generation Sequencing (NGS) panels represent a more comprehensive approach to genetic testing, allowing for the simultaneous analysis of multiple genes associated with various cardiac disorders. Unlike targeted sequencing, NGS panels offer greater flexibility and scalability, enabling the inclusion of genes across different disease categories, such as cardiomyopathies, channelopathies and conduction disorders. This broader gene coverage increases the likelihood of identifying causative variants, especially in cases where the phenotype is ambiguous or overlaps with multiple cardiac conditions. NGS panels are particularly advantageous in USCD cases characterized by phenotypic heterogeneity or when there is limited clinical information available [2].

Literature Review

In select cases where initial genetic testing yields inconclusive results or when there is a high index of suspicion for a rare or novel genetic variant, Whole Exome Sequencing (WES) may be pursued. WES involves sequencing the protein-coding regions of the genome, known as the exome, which constitutes approximately 1-2% of the total genome but harbors the majority of disease-causing variants. While more expensive and technically demanding than targeted sequencing or NGS panels, WES offers the advantage of interrogating the entire exome for potential pathogenic variants, including those in genes not traditionally associated with cardiac disorders. This comprehensive approach is particularly valuable in identifying novel or unexpected genetic etiologies in USCD cases with elusive phenotypes or complex inheritance patterns [3].

Despite the promise of genetic testing in USCD cases, several challenges and limitations must be acknowledged. Variant interpretation remains a significant hurdle, particularly in cases where the clinical significance of identified variants is uncertain. Distinguishing between benign variants, Variants of Uncertain Significance (VUS) and pathogenic variants requires careful evaluation and often necessitates functional studies or segregation analysis within families. Moreover, the psychological impact of genetic testing results on patients and their families cannot be understated, highlighting the importance of comprehensive pre- and post-test genetic counseling. Genetic testing plays a pivotal role in the evaluation of unexplained sudden cardiac death cases, offering valuable insights into the underlying genetic factors contributing to these tragic events. By leveraging targeted sequencing, next-generation sequencing panels and whole exome sequencing, clinicians can identify inherited cardiac conditions that may otherwise go undetected, enabling timely interventions to prevent further tragedies. However, the interpretation of genetic variants and the provision of genetic counseling remain paramount, underscoring the need for multidisciplinary collaboration among clinicians, geneticists and counselors in managing USCD cases effectively [4].

In addition to variant interpretation and genetic counseling, several other challenges must be addressed to optimize the utility of genetic testing in USCD cases. One such challenge is the identification of novel disease-causing genes and variants, particularly in cases where no pathogenic variants are identified through conventional testing methods. Collaborative efforts between clinicians, researchers and genetic consortia are essential for elucidating the genetic architecture of cardiac disorders and expanding the repertoire of genes included in genetic testing panels. Furthermore, the integration of genetic testing into routine clinical practice remains uneven, with disparities in access and utilization across different healthcare settings. Education and awareness initiatives targeting healthcare providers, patients and families are crucial for promoting the adoption of genetic testing and facilitating informed decision-making regarding testing options and implications [5].

Discussion

The Ethical, Legal and Social Implications (ELSI) of genetic testing in USCD cases warrant careful consideration. Issues such as privacy, consent, genetic discrimination and the equitable distribution of testing resources must be addressed to ensure the responsible and equitable implementation of genetic testing technologies. Emerging technologies such as Whole Genome Sequencing (WGS) hold promise for further advancing our understanding of the genetic basis of USCD. WGS offers a comprehensive view of the entire genome, including non-coding regions and structural variants, which may harbor important genetic determinants of cardiac phenotypes. However, the clinical utility, cost-effectiveness and scalability of WGS in USCD cases require further evaluation and validation. Additionally, the integration of genetic testing with other diagnostic modalities, such as cardiac imaging and electrophysiological studies, may enhance risk stratification and personalized management approaches for individuals at risk of USCD. Multimodal approaches that combine genetic, clinical and imaging data hold potential for improving prognostication and guiding the selection of appropriate interventions, including pharmacological therapy, Implantable Cardioverter-Defibrillator (ICD) placement and lifestyle modifications [6].

Conclusion

Genetic testing represents a powerful tool in the evaluation of unexplained sudden cardiac death cases, offering valuable insights into the underlying genetic factors contributing to these tragic events. By addressing challenges related to variant interpretation, genetic counseling, access and implementation and by embracing emerging technologies and multidisciplinary collaboration, we can harness the full potential of genetic testing to inform clinical decision-making, improve patient outcomes and prevent further instances of sudden cardiac death in at-risk individuals and families.

Acknowledgement

We thank the anonymous reviewers for their constructive criticisms of the manuscript.

Conflict of Interest

The author declares there is no conflict of interest associated with this manuscript.

References

1. Papadakis, Michael, Efstathios Papatheodorou, Greg Mellor and Hariharan Raju, et al. "The diagnostic yield of Brugada syndrome after sudden death with normal autopsy." J Am Coll Cardiol 71 (2018): 1204-1214.

Google Scholar, Crossref, Indexed at

2. Page, Matthew J., Joanne E. McKenzie, Patrick M. Bossuyt and Isabelle Boutron, et al. "The PRISMA 2020 statement: An updated guideline for reporting systematic reviews." Bmj 372 (2021).

Google Scholar, Crossref, Indexed at

3. Campuzano, Oscar, Olallo Sanchez-Molero, Catarina Allegue and Monica Coll, et al. "Post-mortem genetic analysis in juvenile cases of sudden cardiac death." Forensic Sci Int 245 (2014): 30-37.

Google Scholar, Crossref, Indexed at

4. Santori, Montserrat, Alejandro Blanco-Verea, Rocio Gil and Judith Cortis, et al. "Broad-based molecular autopsy: A potential tool to investigate the involvement of subtle cardiac conditions in sudden unexpected death in infancy and early childhood." Arch Dis Child 100 (2015): 952-956.

Google Scholar, Crossref, Indexed at

5. Siskind, Tamar, Nori Williams, Monisha Sebastin and Robert Marion, et al. "Genetic screening of relatives of decedents experiencing sudden unexpected death: Medical examiner’s office referrals to a multi-disciplinary cardiogenetics program." J Community Genet 13 (2022): 629-639.

Google Scholar, Crossref, Indexed at

6. Neubauer, Jacqueline, Christine K. Kissel, Stephan A. Bolliger and Daniela Barbon, et al. "Benefits and outcomes of a new multidisciplinary approach for the management and financing of sudden unexplained death cases in a forensic setting in Switzerland." Forensic Sci Int 334 (2022): 111240.

Google Scholar, Crossref, Indexed at